Search

Displaying results 3831 - 3840 of 9702 in total
  1. Drug

    DS-1211

    go.drugbank.com/drugs/DB17837
    Investigational

    DS-1211 is a potent and selective novel small molecule tissue-nonspecific alkaline phosphatase (TNAP) inhibitor.[A259786]

  2. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

  3. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701] … It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.

  4. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  5. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  6. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.

  7. Drug

    MANF

    go.drugbank.com/drugs/DB17885
    Experimental

    MANF is a human recombinant mesencephalic, astrocyte-derived neurotrophic factor.

  8. Drug

    GIVI-MPC

    go.drugbank.com/drugs/DB17905
    Experimental

    GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.

  9. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.[L47067]

  10. Drug

    Bepranemab

    go.drugbank.com/drugs/DB17945
    Investigational

    Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.